DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
The amended claims dated 8/7/2026 are under consideration.
The amendments and arguments presented in the papers filed 8/7/2026 ("Remarks”) have been thoroughly considered. The issues raised in the Office action dated 6/3/2026 listed below have been reconsidered as indicated.
a) The objection of the drawings are withdrawn in view of the replacement sheets providing SEQ ID NOs.
b) The amendments to the application addressing nucleotide sequence disclosure requirements are acknowledged.
c) Any objections or rejections of claim 5 are rendered moot in view of the cancellation of the claim.
d) The prior objections of claims 4 and 10 are withdrawn in view of the amendments to the claims.
The Examiner’s responses to the Remarks regarding issues not listed above are detailed below in this Office action.
New and modified grounds of rejection necessitated by amendment are detailed below and this action is made FINAL.
Election/Restrictions
Applicant elected without traverse Group III, claims 4-8 and 10, in the reply filed on 5/8/2026.
Claims 1, 2, 3, 9 and 11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 5/8/2026.
The species election requirement of 4/1/2026 was withdrawn.
Priority
The present application is a continuation of PCT/CN2022/109999 (filed 8/3/2022) and claims benefit of foreign application CHINA 202111401727.7 (filed 11/19/2021).
Priority is recognized in view of the certified translation of the foreign application CHINA 202111401727.7.
Information Disclosure Statement
The references cited by the examiner on form PTO-892 or on a submitted IDS have been considered.
Claim Objections
Claim 4 is objected to because of the following informalities: the claim lacks a conjunction between the primer pairs. For example, “…group 3: SEQ ID NO: 10 and SEQ ID NO: 11; or group 4: SEQ ID NO: 14 and SEQ ID NO: 15”. Appropriate correction is required.
Claim 4 is objected to because of the following informalities: the claim lacks a conjunction between the barcodes amplified by different Group primer pairs. For example, “…Group 1 primer pair: SEQ ID NO:3, SEQ ID NO: 4, and SEQ ID NO: 5; barcode group B which is amplified by Group 2 primer pair: SEQ ID NO: 8 and SEQ ID NO: 9;…”. Appropriate correction is required.
Claim 4 is objected to because of the following informalities: the claim recites “group 1”, “group 2”, “group 3” and “group 4” and “Group 1”, “Group 2”, “Group 3” and “Group 4”. It is suggested a consistent format be used throughout the claim when referencing a particular claim element. Appropriate correction is required.
Claim 4 is objected to because of the following informalities: the claim lacks a conjunction between the option (iii) and option (iv) of the “fragment characteristic rules”. Appropriate correction is required.
Claim 10 is objected to because of the following informalities: the claim lacks a conjunction between the primers pairs. For example, “…group: SEQ ID NO: 10 and SEQ ID NO: 11; or group 4: SEQ ID NO: 14 and SEQ ID NO: 15”. Appropriate correction is required.
Claim Interpretation
The term “DNA barcode” is interpreted in view of the instant specification as “conserved and stable genetic DNA sequences in a genome” (para. 4).
Claim 10 recites “when testing samples with the product, testing judgment must strictly follow the fragment characteristic rules defined in step S4 of Claim 4 to identify high total polysaccharide Floccularia luteovirens strains”. The claim does not require “testing samples” or making “testing judgements”. The claim language is interpreted as not limiting the scope of how the method is performed.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 4, 6, 7, and 8 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement.
The following are new rejections necessitated by the amendments to the claims.
The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Regarding claim 4, the claim has been amended to recite
“each primer pair is composed of the full-length nucleotide sequences set forth in one of the following four groups, and no arbitrary extra nucleotides can be added to the 5’ end or 3’ end of the core marker sequence of any primer pair”.
The instant specification does not use the phrase “no arbitrary extra nucleotides”. The instant specification does not use the phrase “core marker sequence”.
The instant specification provides no guidance as to what is a “core marker sequence”. The instant specification describes amplified sequences and SSR repetitive elements, but does not identify which, if either, are “core marker sequences”. Furthermore, the instant specification does not identify or provide guidance as to what extra nucleotides may be added to the “core marker sequences” or what types of nucleotides are “arbitrary”. For example, are random n-mer unique molecular identifier sequences “arbitrary” sequences excluded from the present claimed methods?
The above language encompasses new matter as the particular amplicons and SSR repetitive elements disclosed in the specification are not a sufficient number of species so as to represent the genus of “core marker sequences” with “no arbitrary extra nucleotides” added to the 5’ end or the 3’ end.
Claims 6, 7 and 8 depend from claim 4 and are rejected for the same reason.
Claim 10 as amended recites the same language as claim 4. The claim is rejected for the same reason as claim 4 detailed above.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 4, 6-8 and 10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The following are new rejections necessitated by the amendments to the claims.
Regarding claim 4, the claim recites “each primer pair is composed of the full-length nucleotide sequences set forth in one of the following four groups, and no arbitrary extra nucleotides can be added to the 5’ end or 3’ end of the core marker sequence of any primer pair”. It is unclear what nucleotides may be added to the “core marker” and which nucleotides are considered to be “arbitrary”. The instant specification does not provide any guidance as to what is and is not excluded as an “arbitrary extra nucleotide”. For example, it is unclear whether random n-mer unique molecular identifier sequences are “arbitrary” sequences excluded from the present claimed methods?
Regarding claim 4, it is unclear what are the metes and bounds of “the core marker sequence”. The instant specification does not identify what is considered to be the “core marker sequence”.
Regarding claim 4, the claim recites
each primer pair amplifies the corresponding full-length DNA barcodes, and the DNA barcodes only adopt the complete full-length sequences as listed below without any additional terminal base extensions:
barcode group A which is amplified by Group 1 primer pair: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5;
barcode group B which is amplified by Group 2 primer pair: SEQ ID NO:8, SEQ ID NO:9;
barcode group C which is amplified by Group 3 primer pair: SEQ ID NO:12, SEQ ID NO:13;
barcode group D which is amplified by Group 4 primer pair: SEQ ID NO:16, SEQ ID NO:17.
It is unclear whether using primers comprising SEQ ID NO: 1 and SEQ ID NO: 2 amplify each of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or amplify SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 because the claim does not include an conjunction between the three SEQ ID NOs.
It is unclear whether using primers comprising SEQ ID NO: 6 and SEQ ID NO: 7 amplify each of SEQ ID NO: 8 and SEQ ID NO: 9 or amplify SEQ ID NO: 8 or SEQ ID NO: 9 because the claim does not include an conjunction between the two SEQ ID NOs.
It is unclear whether using primers comprising SEQ ID NO: 10 and SEQ ID NO: 11 amplify each of SEQ ID NO: 12 and SEQ ID NO: 13 or amplify SEQ ID NO: 12 or SEQ ID NO: 13 because the claim does not include an conjunction between the two SEQ ID NOs.
It is unclear whether using primers comprising SEQ ID NO: 14 and SEQ ID NO: 15 amplify each of SEQ ID NO: 16 and SEQ ID NO: 17 or amplify SEQ ID NO: 16 or SEQ ID NO: 17 because the claim does not include an conjunction between the two SEQ ID NOs.
Regarding claim 4, the claim recites “subjecting the amplification products obtained from Step S2”. The claim is incomplete because as amended Step S2 does not require an active method step of “performing a fluorescent PCR amplification”. Step S2 positively recites “taking the genomic DNA extracted in Step S1 as a template”. The claim as amended then describes how the extracted genomic DNA may be utilized as a template. The lack of requiring an active step of “performing a fluorescent PCR amplification” results in a gap between elements of Step S2 and Step S3.
Regarding claim 4, the claim recites “including…corresponding repeat times”. It is unclear what is encompassed by a “corresponding repeat times”.
Regarding claim 4, the claim recites “judging whether the tested Floccularia luteovirens strain has high total polysaccharide content according to the detected electrophoresis fragment profiles”. The claim is incomplete because as amended Step S3 does not require an active method step of “detecting a fragment profile”. Step S3 positively recites “subject the amplification products obtained from Step S2 to capillary fluorescence electrophoresis”. The claim as amended then describes the intended use of the capillary fluorescence electrophoresis. The lack of requiring an active step of “detecting fragment profiles” results in a gap between elements of Step S3 and Step S4.
Regarding claim 4, the claim recites “the detected electrophoresis fragment profiles”. The recitation lacks proper antecedent basis as the claim states the intended use of step S3 is to “detect fragment profiles” but does not actively require “detecting fragment profiles”.
Regarding claim 4, the claim recites “the tested Floccularia luteovirens strain” in the first line of Step S4. The recitation lacks proper antecedent basis as the claim does not previously set forth or require a “Floccularia luteovirens strain” but rather the claim involves a “Floccularia luteovirens sample to be tested”.
Claims 6, 7 and 8 depend from claim 4 and are rejected for the same reason.
Regarding claim 6, the claim recites “the fluorescent PCR amplification reaction in step S2”. The recitation lacks proper antecedent basis as the claim states the intended use of step S2 is to “perform a fluorescent PCR amplification”.
Regarding claim 8, the claim recites “the fluorescent PCR amplification reaction in step S2”. The recitation lacks proper antecedent basis as the claim states the intended use of step S2 is to “perform a fluorescent PCR amplification”.
Regarding claim 10, the claim recites “each primer pair is composed of the full-length nucleotide sequences set forth in one of the following four groups, and no arbitrary extra nucleotides can be added to the 5’ end or 3’ end of the core marker sequence of any primer pair”. It is unclear what nucleotides may be added to the “core marker” and which nucleotides are considered to be “arbitrary”. The instant specification does not provide any guidance as to what is and is not excluded as an “arbitrary extra nucleotide”. For example, it is unclear whether random n-mer unique molecular identifier sequences are “arbitrary” sequences excluded from the present claimed methods?
Regarding claim 10, it is unclear what are the metes and bounds of “the core marker sequence”. The instant specification does not identify what is considered to be the “core marker sequence”.
Regarding claim 10, the claim recites
each primer pair amplifies the corresponding full-length DNA barcodes, and the DNA barcodes only adopt the complete full-length sequences as listed below without any additional terminal base extensions:
barcode group A which is amplified by Group 1 primer pair: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5;
barcode group B which is amplified by Group 2 primer pair: SEQ ID NO:8, SEQ ID NO:9;
barcode group C which is amplified by Group 3 primer pair: SEQ ID NO:12, SEQ ID NO:13;
barcode group D which is amplified by Group 4 primer pair: SEQ ID NO:16, SEQ ID NO:17.
It is unclear whether using primers comprising SEQ ID NO: 1 and SEQ ID NO: 2 amplify each of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 or amplify SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 because the claim does not include an conjunction between the three SEQ ID NOs.
It is unclear whether using primers comprising SEQ ID NO: 6 and SEQ ID NO: 7 amplify each of SEQ ID NO: 8 and SEQ ID NO: 9 or amplify SEQ ID NO: 8 or SEQ ID NO: 9 because the claim does not include an conjunction between the two SEQ ID NOs.
It is unclear whether using primers comprising SEQ ID NO: 10 and SEQ ID NO: 11 amplify each of SEQ ID NO: 12 and SEQ ID NO: 13 or amplify SEQ ID NO: 12 or SEQ ID NO: 13 because the claim does not include an conjunction between the two SEQ ID NOs.
It is unclear whether using primers comprising SEQ ID NO: 14 and SEQ ID NO: 15 amplify each of SEQ ID NO: 16 and SEQ ID NO: 17 or amplify SEQ ID NO: 16 or SEQ ID NO: 17 because the claim does not include an conjunction between the two SEQ ID NOs.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claims 6, 7 and 8 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Regarding claim 6, the claim further describes a reaction system of “the fluorescent PCR amplification reaction in step S2”. As noted above, step S2 does not require the active performance of a fluorescent PCR amplification”. Claim 6 fails to further limit step S2 of claim 4 as well as claim 4 in general. Claim 6 does not change the scope of how the active method steps are broadly performed.
Claim 7 depends from claim 6 and is rejected for the same reason.
Regarding claim 8, the claim further describes a “fluorescent PCR amplification reaction procedure in step S2”. As noted above, step S2 does not require the active performance of a fluorescent PCR amplification”. Claim 8 fails to further limit step S2 of claim 4 as well as claim 4 in general.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Conclusion
No claims allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH G DAUNER whose telephone number is (571)270-3574. The examiner can normally be reached 7 am EST to 4:30 EST with second Fridays Off.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng Winston Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOSEPH G. DAUNER/ Primary Examiner, Art Unit 1682